NasdaqCM:TGTXBiotechs
TG Therapeutics' BRIUMVI Data Supports Simplified Regimen And Valuation Upside
TG Therapeutics reported positive Phase 3 ENHANCE results for BRIUMVI, confirming a single 600 mg Day 1 infusion is bioequivalent to the current two-infusion initiation regimen for multiple sclerosis.
The simplified regimen is intended to reduce treatment burden for patients and infusion centers while maintaining safety and efficacy outcomes seen in the trial.
The company plans to submit these data to regulators, aiming to update the BRIUMVI label pending review and approval.
For investors...